ETTX stock forecast
Our latest prediction for Entasis Therapeutics Holdings Inc's stock price was made on the June 11, 2021 when the stock price was at 2.68$.
In the short term (2weeks), ETTX's stock price should outperform the market by 5.39%. During that period the price should oscillate between -10.15% and +18.78%.
In the medium term (3months), ETTX's stock price should underperform the market by -3.86%. During that period the price should oscillate between -44.52% and +43.00%.Get email alerts
Create a solid portfolio with ETTX
About Entasis Therapeutics Holdings Inc
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
At the moment the company generates 7M USD in revenues.
On its last earning announcement, the company reported a loss of -1.24$ per share.
The book value per share is 4.13$
Three months stock forecastJune 11, 2021
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|